We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global POC Testing Market to Reach USD 30 Billion by 2022

By LabMedica International staff writers
Posted on 18 Sep 2019
The global Point-of-Care (POC) testing market is projected to reach USD 30 billion by 2022, driven by the immense potential of POC tests to improve global health and eventually reduce public and national spending on health.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

POC testing devices have now found applications in a large number of medical conditions and their increased usage in the field of critical care settings for delivering decentralized, patient-centric healthcare to patients is expected to drive a rapid growth in the POC testing market. More...
Increasing awareness about POCT, technological advancements and increasing FDA approvals are the major drivers of the global POC testing market. However, some challenges, such as product recalls and lack of regulatory standards, are hindering market growth.

On the basis of type of product, glucose monitoring kits accounted for the largest market share in 2017 due to the rising prevalence of diabetes & technological advancements in self-monitoring of blood glucose. Based on geography, North America accounted for the largest share of the global POC testing market in 2017.

Related Links:
Research and Markets


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Urine samples can indicate lupus nephritis without the need for repeat and painful renal biopsies (Photo courtesy of Shutterstock)

Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients

Lupus is an autoimmune disorder that causes the immune system to attack the body’s own tissues and organs. Among the five million people living with lupus globally, nearly half develop lupus nephritis,... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.